West Nile virus

West Nile virus
Cynthia Goldsmith, P.E. Rollin, USCDCP · CC0 · source
Name	West Nile virus
Field	Virology, Infectious disease, Epidemiology
Symptoms	Fever, headache, encephalitis, meningitis, myelitis
Complications	Neuroinvasive disease, flaccid paralysis, long-term cognitive impairment
Onset	2–14 days after exposure
Causes	Flavivirus infection
Risks	Mosquito exposure, advanced age, immunosuppression
Prevention	Mosquito control, repellents, surveillance, vaccine development
Treatment	Supportive care, hospitalisation for severe disease
Prognosis	Most recover fully; possible persistent neurological sequelae
Frequency	Periodic outbreaks worldwide

West Nile virus West Nile virus is an arthropod-borne Flavivirus first isolated in Uganda; it is a zoonotic pathogen that causes sporadic outbreaks of febrile illness and neuroinvasive disease in humans, birds, and other vertebrates. Since emergence in new regions it has been documented in surveillance reports from New York City, Israel, Italy, Greece and across Sub-Saharan Africa, producing public health responses involving vector control, blood safety, and veterinary measures. Research on genomics, ecology, and clinical management has involved institutions such as the Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health and university laboratories worldwide.

Virology and Genetics

West Nile virus belongs to the genus Flavivirus in the family Flaviviridae and is an enveloped, positive-sense single-stranded RNA virus related to Dengue virus, Zika virus, Yellow fever virus and Japanese encephalitis virus. The ~11 kb genome encodes a single open reading frame translated into structural proteins (capsid, prM/M, envelope) and nonstructural proteins (NS1–NS5) implicated in replication, immune evasion and virulence; comparative genomics studies by teams at Rockefeller University, Johns Hopkins University, and the Pasteur Institute have characterized lineage divergence. Phylogenetic analyses separate strains into multiple lineages, notably lineage 1 and lineage 2, with sequence variation in the envelope protein and NS5 polymerase correlating with geographic spread documented in datasets curated by the European Centre for Disease Prevention and Control and the American Association of Veterinary Laboratory Diagnosticians. Structural biology investigations using cryo-electron microscopy at Harvard University and Swiss Federal Institute of Technology Zurich have resolved envelope protein conformations relevant to neutralizing antibody binding and vaccine antigen design.

Transmission and Epidemiology

Transmission cycles are primarily enzootic between ornithophilic Culex mosquitoes and passerine birds; human infections are incidental dead-end events due to low-level viremia insufficient for mosquito-to-human-to-mosquito amplification. Epidemics in New York City in 1999 and later spread across North America, with subsequent incursions in Europe (notably Romania and Greece) and reports from Australia-adjacent regions, reflect complex interactions among vector ecology, avian migration (studied by groups at the Cornell Lab of Ornithology), urbanization, and climate variability assessed by the Intergovernmental Panel on Climate Change. Other transmission routes include transfusion-transmitted infections documented by the American Association of Blood Banks, organ transplantation events noted in reports from the United Network for Organ Sharing, vertical transmission in rare case series, and laboratory exposures described in incident reports from the Occupational Safety and Health Administration.

Clinical Manifestations and Pathogenesis

Clinical spectrum ranges from asymptomatic seroconversion to West Nile fever — characterized by fever, myalgias and rash — to neuroinvasive disease manifesting as meningitis, encephalitis or acute flaccid paralysis. Risk of severe neuroinvasion increases with advancing age and immunocompromise; cohort studies from Mayo Clinic, Mount Sinai Health System and multicenter registries coordinated by the Infectious Diseases Society of America have quantified morbidity and mortality. Pathogenesis involves viral entry into peripheral tissues, hematogenous spread, blood–brain barrier disruption, and direct neuronal infection and immune-mediated damage; experimental models developed at Columbia University and The Scripps Research Institute have delineated roles for NS proteins, host interferon responses, and microglial activation. Neurological sequelae documented in longitudinal follow-up studies include persistent cognitive deficits, movement disorders, and chronic fatigue syndromes referenced in publications from Johns Hopkins Medicine and Cleveland Clinic.

Diagnosis and Laboratory Testing

Laboratory diagnosis relies on serology detecting specific IgM and IgG antibodies in serum or cerebrospinal fluid using enzyme-linked immunosorbent assays and neutralization tests standardized by the Centers for Disease Control and Prevention; cross-reactivity with other flaviviruses such as Dengue virus necessitates confirmatory plaque-reduction neutralization tests in reference laboratories including the World Reference Laboratory Network. Molecular detection by reverse transcription PCR of viral RNA in blood, cerebrospinal fluid, or tissues is most sensitive early in infection and is deployed in clinical laboratories affiliated with Mayo Clinic Laboratories and public health labs coordinated by the Association of Public Health Laboratories. Viral culture is restricted to biosafety level 3 facilities such as those accredited by the American Type Culture Collection and used primarily for research, while next-generation sequencing applied in outbreak investigations has been implemented by consortia including researchers at Imperial College London and the Wellcome Trust Sanger Institute.

Prevention and Control

Prevention emphasizes integrated vector management, personal protective measures (EPA-registered repellents), community-based mosquito habitat reduction programs run by municipal health departments (examples include programs in Los Angeles and Chicago), and blood donor screening policies instituted by national blood services like the American Red Cross and NHS Blood and Transplant. Avian surveillance conducted by wildlife agencies such as the US Fish and Wildlife Service and sentinel chicken programs inform public health responses coordinated with the European Centre for Disease Prevention and Control. Vaccine development efforts for humans have been pursued by academic partnerships and biotechnology firms, with licensed vaccines for equids approved by regulatory agencies including the US Department of Agriculture; clinical trials overseen by the Food and Drug Administration and European Medicines Agency continue for human candidates.

Treatment and Management

No specific antiviral therapy with proven clinical efficacy is licensed for human disease; management is supportive and includes hospital-level care for neuroinvasive disease with airway management, seizure control following protocols from American Heart Association and Neurocritical Care Society, and rehabilitation services coordinated with tertiary centers such as Spaulding Rehabilitation Hospital. Investigational therapeutics — monoclonal antibodies, small-molecule antivirals, and immunomodulators — have advanced to early-phase trials conducted with oversight by the National Institutes of Health and industry partners including biotechnology companies listed on stock exchanges such as NASDAQ. Public health case management integrates reporting to national surveillance systems like those maintained by the Centers for Disease Control and Prevention and outbreak response coordination with agencies such as the World Health Organization.

Category:Flaviviruses